by TractManager | Jul 30, 2020 | Emerging Technology Report
Dexamethasone is a glucocorticoid that is FDA-approved for numerous indications; it is under investigation for the treatment of COVID-19. Glucocorticoids are adrenocortical steroids that modify the body’s immune responses to diverse stimuli. Dexamethasone is...
by TractManager | Jul 29, 2020 | Health Technology Assessment
Focus of the Report: This report evaluates the efficacy and safety of the gene replacement therapy onasemnogene abeparvovec-xioi (Zolgensma or AVXS-101) for treatment of patients with spinal muscular atrophy (SMA) type 1.Technology Description: Onasemnogene...
by TractManager | Jul 28, 2020 | COVID-News, News
These Food and Drug Administration (FDA) developments came in this week:FDA Reissues EUA for COVID-19 Diagnostic TestThe FDA has reissued the emergency use authorization (EUA) for the LabCorp COVID-19 RT-PCR Test to include two new indications for use: testing for...
by TractManager | Jul 27, 2020 | News
On July 24, 2020, the Food and Drug Administration (FDA) approved a biologics license application (BLA) for Tecartus (brexucabtagene autoleucel, Kite Pharma Inc.) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).Tecartus, a...
by TractManager | Jul 24, 2020 | Emerging Technology Report
The interatrial shunt device (IASD) is a transcatheter interatrial shunt for treatment of heart failure with preserved or borderline reduced ejection fraction. It is proposed to decrease elevated left atrial pressure in patients with heart failure and preserved or...
Recent Comments